决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma.
背景:弥漫大B细胞淋巴瘤(DLBCL)被认为是淋巴瘤最常见的亚型,是一种侵袭性肿瘤。
背景:弥漫大B细胞淋巴瘤(DLBCL)是最常见的淋巴瘤亚型,具有侵袭性。程序性坏死是一种新型程序性细胞死亡,在肿瘤中具有双向作用,并可通过参与肿瘤微环境影响肿瘤发展。靶向程序性坏死是一个值得探索的方向,其在DLBCL中的作用仍需进一步研究。方法:通过单变量Cox回归筛选获得17个DLBCL相关程序性坏死基因;依据GSE31312中这些基因的表达进行聚类,并比较不同簇的临床特征。采用Kaplan-Meier法比较各簇预后,并通过ESTIMATE、CIBERSORT及单样本基因集富集分析(ssGSEA)研究不同程序性坏死簇的肿瘤免疫微环境(TME)差异。最后通过LASSO-Cox回归构建6基因预后模型,并结合临床特征建立预后列线图。结果:分析提示程序性坏死在DLBCL中具有稳定但不同的作用模式。根据程序性坏死相关基因及聚类相关基因,识别出三个患者组,其预后、TME和化疗药物敏感性均有显著差异。免疫浸润分析显示,预后最佳的第1簇显著浸润NKT细胞、树突状细胞、CD8阳性T细胞和M1巨噬细胞;第3簇则有M2巨噬细胞浸润且预后最差。预后模型可有效区分高低风险患者并预测生存;纳入预测性临床特征后,列线图也能较好预测DLBCL患者生存时间。结论:程序性坏死模式差异有助于解释其调节DLBCL免疫微环境及对R-CHOP治疗应答的作用。系统评估DLBCL患者的程序性坏死模式,有助于理解肿瘤微环境细胞浸润特征并制定个体化治疗方案。
Background: Diffuse large B-cell lymphoma (DLBCL), which is considered to be the most common subtype of lymphoma, is an aggressive tumor. Necroptosis, a novel type of programmed cell death, plays a bidirectional role in tumors and participates in the tumor microenvironment to influence tumor development. Targeting necroptosis is an intriguing direction, whereas its role in DLBCL needs to be further discussed. Methods: We obtained 17 DLBCL-associated necroptosis-related genes by univariate cox regression screening. We clustered in GSE31312 depending on their expressions of these 17 genes and analyzed the differences in clinical characteristics between different clusters. To investigate the differences in prognosis across distinct clusters, the Kaplan-Meier method was utilized. The variations in the tumor immune microenvironment (TME) between distinct necroptosis-related clusters were investigated via "ESTIMATE", "Cibersort" and single-sample geneset enrichment analysis (ssGSEA). Finally, we constructed a 6-gene prognostic model by lasso-cox regression and subsequently integrated clinical features to construct a prognostic nomogram. Results: Our analysis indicated stable but distinct mechanism of action of necroptosis in DLBCL. Based on necroptosis-related genes and cluster-associated genes, we identified three groups of patients with significant differences in prognosis, TME, and chemotherapy drug sensitivity. Analysis of immune infiltration in the TME showed that cluster 1, which displayed the best prognosis, was significantly infiltrated by natural killer T cells, dendritic cells, CD8 + T cells, and M1 macrophages. Cluster 3 presented M2 macrophage infiltration and the worst prognosis. Importantly, the prognostic model successfully differentiated high-risk from low-risk patients, and could forecast the survival of DLBCL patients. And the constructed nomogram demonstrated a remarkable capacity to forecast the survival time of DLBCL patients after incorporating predictive clinical characteristics. Conclusion: The different patterns of necroptosis explain its role in regulating the immune microenvironment of DLBCL and the response to R-CHOP treatment. Systematic assessment of necroptosis patterns in patients with DLBCL will help us understand the characteristics of tumor microenvironment cell infiltration and aid in the development of tailored therapy regimens.
MEMBER ACCOUNT
登录成功会直接打开下一页。